Free Trial

Humacyte (HUMA) Competitors

Humacyte logo
$2.33 -0.09 (-3.72%)
Closing price 04:00 PM Eastern
Extended Trading
$2.39 +0.06 (+2.58%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HUMA vs. EWTX, TVTX, CVAC, PAHC, ABCL, CALT, HROW, WVE, AMPH, and GPCR

Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Edgewise Therapeutics (EWTX), Travere Therapeutics (TVTX), CureVac (CVAC), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Calliditas Therapeutics AB (publ) (CALT), Harrow (HROW), WAVE Life Sciences (WVE), Amphastar Pharmaceuticals (AMPH), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

Humacyte vs. Its Competitors

Humacyte (NASDAQ:HUMA) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Edgewise Therapeutics has lower revenue, but higher earnings than Humacyte. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Humacyte$1.57M230.21-$148.70M-$0.69-3.38
Edgewise TherapeuticsN/AN/A-$133.81M-$1.55-8.74

In the previous week, Edgewise Therapeutics had 3 more articles in the media than Humacyte. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 1 mentions for Humacyte. Humacyte's average media sentiment score of 0.49 beat Edgewise Therapeutics' score of 0.47 indicating that Humacyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Humacyte
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Edgewise Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Humacyte has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Humacyte currently has a consensus price target of $11.71, indicating a potential upside of 402.76%. Edgewise Therapeutics has a consensus price target of $40.00, indicating a potential upside of 195.42%. Given Humacyte's stronger consensus rating and higher possible upside, equities research analysts clearly believe Humacyte is more favorable than Edgewise Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humacyte
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00
Edgewise Therapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

44.7% of Humacyte shares are owned by institutional investors. 5.1% of Humacyte shares are owned by insiders. Comparatively, 23.2% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Humacyte's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
HumacyteN/A N/A -73.59%
Edgewise Therapeutics N/A -30.95%-29.45%

Summary

Humacyte beats Edgewise Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Humacyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HUMA vs. The Competition

MetricHumacyteMED IndustryMedical SectorNASDAQ Exchange
Market Cap$375.39M$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E RatioN/A8.2821.0120.09
Price / Sales230.21303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book-5.687.678.125.65
Net Income-$148.70M-$55.28M$3.25B$257.91M
7 Day Performance0.87%2.50%0.97%2.09%
1 Month Performance-1.27%11.70%7.36%11.13%
1 Year Performance-69.88%4.89%31.31%18.40%

Humacyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HUMA
Humacyte
1.5776 of 5 stars
$2.33
-3.7%
$11.71
+402.8%
-70.4%$375.39M$1.57M0.00150
EWTX
Edgewise Therapeutics
1.4953 of 5 stars
$12.61
-3.2%
$40.00
+217.2%
-36.1%$1.33BN/A-8.1460
TVTX
Travere Therapeutics
3.7272 of 5 stars
$14.60
-2.7%
$32.14
+120.2%
+60.4%$1.30B$273.53M-5.20460News Coverage
Analyst Revision
CVAC
CureVac
4.7525 of 5 stars
$5.41
-0.7%
$6.83
+26.3%
+47.9%$1.21B$523.70M5.88880Positive News
PAHC
Phibro Animal Health
4.0498 of 5 stars
$29.90
+6.8%
$24.40
-18.4%
+56.3%$1.21B$1.02B38.331,940News Coverage
High Trading Volume
ABCL
AbCellera Biologics
2.3189 of 5 stars
$4.03
+6.1%
$7.50
+86.1%
+15.7%$1.20B$28.83M-7.20500High Trading Volume
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
HROW
Harrow
2.3814 of 5 stars
$31.36
-1.2%
$61.40
+95.8%
+43.7%$1.15B$199.61M-56.00180Trending News
Analyst Revision
WVE
WAVE Life Sciences
4.5817 of 5 stars
$7.06
+1.6%
$20.50
+190.4%
+35.5%$1.10B$108.30M-8.40240Analyst Forecast
AMPH
Amphastar Pharmaceuticals
4.3171 of 5 stars
$22.86
-1.5%
$32.33
+41.4%
-45.0%$1.08B$731.97M8.282,028
GPCR
Structure Therapeutics
2.9436 of 5 stars
$18.73
-8.0%
$76.17
+306.7%
-49.1%$1.07BN/A-21.53136

Related Companies and Tools


This page (NASDAQ:HUMA) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners